Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907616 | 0.92 | PTGS2 (0.67) | PTGS2PTGS1CYP2C9AOC3 | |
| SCHEMBL4593759 | 0.81 | PTGS2 (0.79) | PTGS2PTGS1CYP2C9AOC3 | |
| SCHEMBL4592993 | 0.81 | MEN1 (0.57) | PTGS2MEN1NPC1LMNARAB9A | |
| SCHEMBL4592621 | 0.81 | PTGS2 (0.52) | PTGS2MEN1NPC1LMNARAB9A | |
| SCHEMBL9202389 | 0.80 | PTGS2 (0.44) | PTGS2MEN1NPC1LMNARAB9A | |
| SCHEMBL9204515 | 0.78 | PTGS2 (0.49) | PTGS2MEN1KMT2APTGS1AOC3 | |
| SCHEMBL6780629 | 0.78 | PTGS2 (0.49) | PTGS2MEN1NPC1LMNARAB9A | |
| SCHEMBL6780624 | 0.78 | PTGS2 (0.49) | PTGS2MEN1NPC1LMNARAB9A | |
| SCHEMBL9207827 | 0.78 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL9205418 | 0.77 | PTGS2 (0.52) | PTGS2MEN1KMT2APTGS1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153569-A1 | Novel pyrazole and pyrazoline substituted compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-14 | — | — | US | claimed |
| US-20020156104-A1 | CSBP/p38/RK kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-24 | — | — | US | claimed |
| EP-1583535-A4 | METHODS FOR TREATING DIABETES | SCIOS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1583535-A2 | METHODS FOR TREATING DIABETES | SCIOS INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20040171659-A1 | Methods for treating diabetes | SCIOS, INC. | 2004-09-02 | — | — | US | disclosed |
| US-6774127-B2 | TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2004-08-10 | — | — | US | disclosed |
| WO-2004053107-A2 | METHODS FOR TREATING DIABETES | SCIOS INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20020156104-A1 | CSBP/p38/RK kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153569-A1 | Novel pyrazole and pyrazoline substituted compounds | PDXK, COQ8A, PDK3 | PTGS2 3455/4885MEN1 3265/4885NPC1 884/4885 |
| US-20040171659-A1 | Methods for treating diabetes | SLC5A2, MAPK4, MAPK3 | PTGS2 315/4885MEN1 4158/4885NPC1 2023/4885 |
| US-20020156104-A1 | CSBP/p38/RK kinase inhibitors | MAPKAPK2, MAPKAPK3, MAPKAPK5 | PTGS2 2606/4885MEN1 4619/4885NPC1 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.